STOCKSCOUTER
StockScouter Premium
StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance
Learn more or Get it now! Stockscouter Portfolio performance
LCTX LINEAGE CELL THERAPEUTICS INCORPORATED StockScouter® Report
4
StockScouter® Score
LINEAGE CELL THERAPEUTICS INCORPORATED, a small cap growth company in the healthcare sector, is expected to perform in line with the market over the next six months with slightly less than average risk
10 is the best possible rating. Learn more.
Summary
Positives
- Earnings growth in the past year has accelerated moderately compared to earnings growth in the past three years. Positive
- The most recent quarterly earnings report higher than analysts’ consensus forecast. Positive
Concerns
- The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
- The multi-period measure of relative price change and consistency is below average. Negative/Neutral
Short-term Outlook
Over the next 1-2 months, StockScouter forecasts that small cap stocks will be neutral, growth stocks will be neutral, and healthcare stocks will be neutral.
Expected Risk/Return
Core Model Grades
B
C
F
D